VRDN — Viridian Therapeutics, Inc. stock price, charts and financials

Latest market price

19.31

+0.39+2.06%

Overview Short InterestFilings

VRDNQT54Viridian Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

19.31+2.06%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

IOVA+6.14%$4.32 FTRE-1.20%$18.94 SLS+12.09%$11.22 URGN+0.92%$38.59 MESO+2.12%$14.47 TSHA-1.37%$5.78 TYRA+0.50%$32.04 AUPH-2.08%$14.57

Snapshot

Index	-	P/E	-	EPS (ttm)	-17.07	Insider Own	31.88%	Shs Outstand	90.00M	Perf Week	-1.82%

Market Cap	1.70B	Forward P/E	-	EPS next Y	-2.49	Insider Trans	4.10%	Shs Float	73.78M	Perf Month	2.38%

Enterprise Value	1.58B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	25.65%	Perf Quarter	40.36%

Income	-317.56M	P/S	24.01	EPS this Y	77.68%	Inst Trans	-	Short Ratio	7.55	Perf Half Y	-43.64%

Sales	70.92M	P/B	3.04	EPS next Y	34.57%	ROA	-45.70%	Short Interest	18.92M	Perf YTD	-39.20%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-60.70%	52W High	34.99 -44.82%	Perf Year	6.29%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-52.27%	52W Low	13.45 43.55%	Perf 3Y	1.07%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	228.66% 134.56%	Gross Margin	99.38%	Volatility	4.23% 4.37%	Perf 5Y	10.00%

Dividend TTM	-	EV/Sales	22.25	EPS Y/Y TTM	16.58%	Oper. Margin	-543.86%	ATR (14)	0.86	Perf 10Y	-84.01%

Dividend Ex-Date	-	Quick Ratio	15.15	Sales Y/Y TTM	-	Profit Margin	-508.46%	RSI (14)	50.68	Recom	2.13

Dividend Gr. 3/5Y	-	Current Ratio	15.15	EPS Q/Q	-3.45%	SMA20	-1.92%	Beta	0.89	Target Price	36.88

Payout	0.00%	Debt/Eq	0.08	Sales Q/Q	-	SMA50	5.38%	Rel Volume	0.43	Prev Close	18.92

Employees	252	LT Debt/Eq	0.07	Earnings	Aug 05	SMA200	-21.14%	Avg Volume	2.52M	Price	19.31

IPO Date	Jun 18, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.74% 290.77%	Net Debt/EBITDA	0.36	Volume	1,088,028	Change	2.06%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-30-26	Reiterated	Goldman Sachs	Buy	$35 → $39
Jun-30-26	Reiterated	Truist Securities	Buy	$35 → $38
Jun-29-26	Reiterated	Truist Financial	Buy	$33 → $35
Jun-29-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$31
May-15-26	Reiterated	Evercore ISI Group	Outperform	$45 → $26
May-13-26	Reiterated	Stifel Nicolaus		$48 → $39
May-06-26	Reiterated	RBC Capital	Outperform	$45 → $34
Apr-21-26	Reiterated	Truist Securities	Buy	$36 → $33
Apr-08-26	Reiterated	Truist Financial	Buy	$40 → $36
Apr-08-26	Reiterated	Wedbush	Outperform	$31

Latest News

Jul-01-26

Jul-01-2606:21AM

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease - SlideshowSeekingAlpha

Jun-30-26

Jun-30-2608:30AM

Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approvalseekingalpha.com

Jun-29-26

Jun-29-2602:12PM

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcriptseekingalpha.com

09:24AM

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Diseasebenzinga.com

Jun-26-26

Jun-26-2606:03PM

Viridian Therapeutics Receives FDA Approval For Lumvoa For The Treatment Of Thyroid Eye Disease; Co. Plans To Launch Lumvoa ImmediatelyBenzinga

Jun-25-26

Jun-25-2601:23AM

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market AppreciatesSeekingAlpha

Jun-10-26

Jun-10-2612:02AM

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha

Company

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	71	0	0	2	3	1	4	8	4
Cost of Goods Sold Incl. D&A	0	0	0	0	0	28	0	30	20
Gross Profit	71	0	0	2	3	-27	4	-22	-16
Selling, General and Administrative Excl. Other	95	61	95	35	26	13	12	11	11
Research and Development	339	238	160	101	57	28	35	30	20
Other Operating Expense	0	0	0	0	0	42	-1	0	0
Operating Income	-363	-299	-254	-134	-80	-110	-42	-33	-27
Interest Expense	5	3	2	0	0	1	1	1	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	26	32	19	5	0	0	1	1	0
Net Income Before Taxes	-343	-270	-238	-130	-79	-111	-42	-33	-27
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-343	-270	-238	-130	-79	-111	-42	-33	-27
Net Income From Continuing Operations	-343	-270	-238	-130	-79	-111	-42	-33	-27
Net Income	-343	-270	-238	-130	-79	-111	-42	-33	-27
EPS (Recurring)	-3.32	-3.98	-5.31	-3.91	-6.66	-31.20	-20.31	-16.57	-20.66
EPS (Basic, Before Extraordinaries)	-3.32	-3.98	-5.31	-3.91	-6.66	-31.20	-20.31	-16.57	-20.66
EPS (Diluted)	-3.32	-3.98	-5.31	-3.91	-6.66	-31.20	-20.31	-16.57	-20.66
EBITDA	-337	-266	-235	-129	-79	-40	-41	-32	-26
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	37.26	—	—	467.36	79.08	65.80	3.60	11.36	39.11
Gross Margin	100.00	—	—	100.00	100.00	-2,700.00	100.00	-275.00	-400.00
Operating Margin	-511.27	—	—	-6,700.00	-2,666.67	-11,000.00	-1,050.00	-412.50	-675.00
Net Margin	-483.10	—	—	-6,500.00	-2,633.33	-11,100.00	-1,050.00	-412.50	-675.00
Shares Outstanding	85	68	45	32	12	4	2	2	1
Market Capitalization	2,645	1,304	980	935	237	66	14	91	156
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	director, 10 percent owner:	May 11 '26	Buy	17.00	1,176,470	19,999,990	5,090,928	May 13
Mahoney Stephen F.	President and CEO	Mar 03 '26	Option Exercise	0.00	18,357	0	40,757	Mar 04
Tousignant Jennifer	Chief Legal Officer	Mar 03 '26	Option Exercise	0.00	5,169	0	5,169	Mar 04
Beetham Thomas W.	Chief Operating Officer	Mar 03 '26	Option Exercise	0.00	9,409	0	16,409	Mar 04
Harmon Seth	Chief Financial Officer	Mar 03 '26	Option Exercise	0.00	6,267	0	9,881	Mar 04
Tousignant Jennifer	Chief Legal Officer	Dec 31 '25	Sale	31.16	2,272	70,796	0	Jan 02
Fairmount Funds Management LLC	director, 10 percent owner:	Oct 23 '25	Buy	22.00	454,545	9,999,990	3,914,458	Oct 27
Fairmount Funds Management LLC	director, 10 percent owner:	Jun 10 '25	Option Exercise	12.31	12,500	153,875	3,459,913	Jun 11
Fairmount Funds Management LLC	director, 10 percent owner:	Jun 09 '25	Option Exercise	7.80	1,600	12,480	3,447,413	Jun 11
Beetham Thomas W.	Chief Operating Officer	Sep 27 '24	Buy	23.41	5,000	117,050	6,000	Sep 30
Mahoney Stephen F.	President and CEO	Sep 27 '24	Buy	23.33	21,400	499,262	21,400	Sep 30
Fairmount Funds Management LLC	director, 10 percent owner:	Sep 13 '24	Buy	18.75	1,600,000	30,000,000	3,445,813	Sep 17
Fairmount Funds Management LLC	director, 10 percent owner, other: See Remarks	Jan 22 '24	Buy	21.00	476,190	9,999,990	1,839,954	Jan 24
Meisner Lara	Chief Legal Officer	Jun 16 '23	Option Exercise	23.03	55	1,267	37,453	Jun 20
Meisner Lara	Chief Legal Officer	Jun 16 '23	Sale	28.35	27	765	29,971	Jun 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.